Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Inhaled corticposteroids (ICS)
corticposteroids · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Lebrikizumab | EXPERIMENTAL | Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab on Days 1 and 8, and on Weeks 4 and 8. |
| Placebo | PLACEBO_COMPARATOR | Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab matching placebo on Days 1 and 8, and on Weeks 4 and 8. |
| Name | Type | Description |
|---|---|---|
| Lebrikizumab | DRUG | Lebrikizumab will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8. |
| Placebo | DRUG | Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8. |
| Inhaled corticposteroids (ICS) | DRUG | Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS. |
| Second Asthma Controller Medication | DRUG | Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study. |
Inclusion Criteria: * Asthma diagnosis for greater than or equal to (\>/=) 12 months prior to Visit 1 * Bronchodilator response demonstrated within the 12 months before Visit 1 or at Visit 1, 2, or 3 of screening * Pre-bronchodilator FEV1 of 40 percent (%) - 80% predicted at both Visits 2 and 3 * O...